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Abstract 
Respiratory viral infections are known to affect equine health worldwide and are 
commonly associated with clinical signs such as fever, cough, and nasal discharge. 
While clinical respiratory signs will prevent horses from training and racing, it is also 
known that horses can be infected by viruses and yet not exhibit any clinical signs (i.e. 
subclinically infected). However, it is not clear whether these subclinical infections 
may have any effect on the horse´s performance and health. In this thesis well-known 
equine respiratory viruses such as equine influenza (EIV) and herpesvirus (EHV) type 1 
and 4, as well as the less explored equine rhinitis A and B virus (ERAV and ERBV) 
and EHV type 2 and 5, were investigated on monthly basis in a longitudinal study over 
a year in actively racing Standardbred trotters. The presence and amount of the viruses 
and their antibodies were identified by diagnostic methods such as serology and PCR 
assays. Genetic information was obtained by sequencing. The health of the horses was 
also monitored and their performance determined by both objective and subjective 
methods. A high seroprevalence of ERAV and ERBV in the samples suggested that 
these viruses were widespread in the study cohort of well-managed horses. EHV-5 and 
EHV-2 were detected in about three-quarters and almost one third of the nasal 
secretions samples respectively. We could however not find any associations between 
these subclinical infections and poor performance. This work also includes a case 
report of equine multinodular pulmonary fibrosis (EMPF) in a horse, which was 
identified with co-infection by EHV-5 and the asinine herpesvirus type 5. Genetic 
analysis of a segment of the gB gene of EHV-5 in healthy horses with two samples 
taken one year apart and from the EMPF case study horse pre and post mortem allowed 
to classify EHV-5 strains into four different genotypes. While viral strains appeared 
stable over time, horses could be infected with multiple strains that varied in detection 
qualitatively and quantitatively over time. The single strain detected in the EMPF case 
was also found in the clinically normal horses. 
The work in this thesis provides knowledge of subclinical presence of respiratory 
viruses in elite Standardbred trotters and further genetic information of EHV-5 showed 
a range of interactions between EHV-5, the host and the environment over time. 
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When you are on a great horse, you have the best seat you will ever have.  
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Respiratory viral infections affect equine health worldwide and are commonly 
associated with clinical signs such as fever, cough, and nasal discharge. 
Outbreaks of respiratory infections, especially caused by equine influenza virus 
(EIV), continue to have major impact on both equine health and welfare and 
causes of financial losses to the industry due to cancelled events or temporarily 
close down of race tracks (Legrand et al., 2013).  
Consequently considerable research has been performed on equine 
respiratory viral infections, preferably those that cause severe clinical disease, 
and the understanding of equine respiratory viral pathogens is continuously 
growing, accompanied by the development of commercial vaccines for EIV 
and equine herpesvirus (EHV) type 1 and 4 infections. Vaccination, together 
with biosecurity, plays an important role in preventing infectious diseases. 
However, it can be challenging to design a vaccine with satisfactory level of 
protection and therefore fully effective vaccines are not always available. 
Vaccines both serve the purpose of protecting the individual horse from 
infection and that of preventing spread from already infected animals. Since 
animals vaccinated against EIV (Elton & Cullinane, 2013; Bryant et al., 2010) 
as well as EHV-1 (Goehring et al., 2010) have been identified to shed lower 
amount of virus compared to unvaccinated horses, vaccination thereby limiting 
the spread of the virus and protecting the wider population of horses from 
infection. 
Optimal function of the respiratory tract is crucial for the horse and its 
athletic performance. Subclinical respiratory abnormalities have been 
associated with exercise intolerance that often appears only at maximal athletic 
exertion (Fraipont et al., 2011; Fogarty & Buckley, 1991). Furthermore, viral 
infections, especially subclinical, have been associated with the poor 
performance syndrome for decades (Mumford & Rossdale, 1980). On many 
occasions, respiratory viruses have been blamed when a horse has performed 
below its expected level of performance. For example, during the last 20 years 
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blood samples from approximately 13 000 Swedish horses have been analysed 
at the National Veterinary Institute (SVA) in Uppsala Sweden for presence of 
antibodies to equine rhinitis viruses (unpublished data) due to suspicion that 
subclinical infections were causing poor performance, despite lack of scientific 
evidence. Equine respiratory viruses in general and herpesviruses in particular 
(due to their high prevalence and capability of latency), have frequently been 
incriminated as reasons for poor performance in athletic horses (Wood et al., 
2005). Supporting the link between viral infection and the poor performance 
syndrome, horses with impaired performance and respiratory problems were 
shown to have significantly higher lactate concentrations in the blood during 
treadmill exercise tests compared to well performing horses (Courouce-
Malblanc et al., 2002). Furthermore, together with lameness, respiratory 
problems such as inflammatory airway disease (IAD) are among the most 
common reasons for race horses failing to race, train and perform as expected 
(Wilsher et al., 2006).  
That a clinical respiratory viral infections can impair athletic performance is 
expected. Thus, the presence of clinical signs of respiratory disease due to viral 
or other infections is a clear indication for horses not to enter competition. It is, 
however, known that horses can be infected by viruses and yet not exhibit any 
clinical signs, widely known as being subclinically infected. The more subtle 
the effects of the subclinical viral infection are, if any, the more uncertain their 
association with the performance of the horse. Moreover, diagnostic methods 
to detect subclinical viral infections have been scarcely evaluated. In addition, 
the lack of a generally accepted definition/measurement of poor performance is 
lacking which prevents comparison between studies. Since poor athletic 
performance often occurs in the absence of obvious clinical disease, these low 
virulent viruses, about which we know little, have become under increased 
scrutiny during the last decades due to their possible association to poor 
athletic performance in the horse.  
In the reminder of this introduction, the main equine respiratory viruses are 
presented, where equine rhinitis viruses and the gamma herpesviruses are 
examples of less known respiratory viruses, including the available evidence of 
their possible clinical significance and influence on poor performance, 
followed by a description of poor performance. The strengths and limitations 
of diagnostic tools we have available to diagnose these various equine 
respiratory viral infections, will be addressed with a final section on the 
relationship between subclinical respiratory viral infection and equine health 
and poor performance.  
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1.1 Equine influenza virus (EIV) 
Equine Influenza Virus (EIV) is an influenza type A virus, a member of the 
Orthomyxoviridae family and is one of the most highly contagious and 
widespread viral respiratory diseases in horses and other equids. The clinical 
signs of equine influenza are characterized mainly by fever, nasal discharge 
and a harsh dry cough, and can predispose to secondary bacterial infections 
(Timoney, 1996).  
      Two different subtypes of EIV, H7N7 and H3N8, have been associated 
with disease in horses. H7N7 was first isolated in Prague in Eastern Europe in 
1956 (Sovinova et al., 1958), but has not been isolated from a horse since 1980 
and is therefore now believed to be extinct (Webster, 1993). The H3N8 
subtype of EIV was first isolated from horses in 1963 and diverged into the 
American and Eurasian sublineage (Daly et al., 1996). However, viruses 
isolated in Europe have been shown to belong to the American lineage and vice 
versa. The American lineage has then diverged into Kentucky, South America 
(Argentina) and Florida (Lai et al., 2001). The Florida sublineage has 
subsequently predominated and, based on HA sequencing, divided further into 
clade 1 and 2 (Bryant et al., 2009). Since 2007, most EIV isolates in Sweden as 
well as in other European countries have been identified as Florida clade 2. In 
Sweden prior to 2007, vaccination was mandatory only for horses competing in 
equestrian sports, but not young horses nor racing trotters. However, following 
the outbreak of EIV in 2007 (unpublished data) mandatory vaccination in the 
Swedish trotting industry was imposed. 
      EIV vaccination was introduced in Europe and North America in the late 
1960s (Cullinane et al., 2010). The majority of the EIV vaccines used today are 
adjuvant inactivated or subunit vaccines, that induce antibodies against the 
haemagglutinin (HA) of the virus which can be measured and correlated with 
protection (Daly et al., 2004; Newton et al., 2000). Since dissemination of EIV 
to wider population of horses after race meetings or other events has been 
clearly documented (Cullinane & Newton, 2013), mandatory vaccination 
among racing and equestrian horses has played an important role in the control 
of EIV. However, due to the continuous antigenic evolution of EIV optimal 
protection requires that the available vaccines are continuously updated with 
the currently circulating strains (Elton & Cullinane, 2013; Gildea et al., 2013). 
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1.2 Equine herpesviruses 
Herpesviruses are large double stranded DNA-viruses that are characterized by 
their persistent lifelong latency (Roizmann et al., 1992). The family 
Herpesviridae and are classified in three subfamilies: Alpha, Beta and 
Gammaherpesvirinae. Of the three subfamilies two are relevant for equine 
health. 
1.2.1 Equine alpha herpesviruses (EHV-1 and EHV-4) 
Equine herpesvirus (EHV) type 1 and 4 are closely related alpha herpesviruses 
included in the genus Varicellovirus with genome sizes of approximately 150 
kbp for EHV-1 (Telford et al., 1992) and 146 kbp for EHV-4 (Telford et al., 
1998). Despite the close relationship between EHV-1 and EHV-4, the existing 
genetic differences are sufficient to give rise to major biological divergences 
where separate affinity for replication sites and cells determine the clinical 
signs. EHV-1 is associated with respiratory disease, abortion in late gestation 
and neurologic disease, whereas EHV-4 mainly results in upper respiratory 
tract disease such as pyrexia, cough, nasal discharge and depression. But the 
infection may also pass asymptomatic in older horses (Allen et al., 2004; 
Crabb & Studdert, 1995).  
      Clinical disease associated with both EHV-1&4 has been a problem for 
both the equine health and the equine industry for a long period of time. 
Already in early 1960 attempts was made to immunise mares and young horses 
against alpha herpesviruses to protect them against clinical disease with 
abortion and respiratory signs (Doll & Bryans, 1963b; Doll & Bryans, 1963a). 
Today vaccines are available on the market, providing some protection from 
the alpha herpesvirus EHV-1&4. However, since herpesviruses activate the 
immune response via both induction of antibodies (short-lived mucosal 
antibodies), and cytotoxic T cells and cytokines (interferons) on a cellular level 
(Kydd et al., 2006), manufacturing of highly protective vaccine is challenging. 
Protection against clinical and virological disease requires both mucosal 
antibodies to reduce viral shedding and to combat free viral particles whereas 
the cytotoxic T cells are essential to lyse infected cells (Allen et al., 1999). 
Despite extensive research over the last decades, no fully protective and long-
term vaccine against the alpha herpesviruses is yet available, as a vaccine that 
can stimulate both humoral and cell-mediated immunity is required for optimal 
protection (Kydd et al., 2012) which provides a challenge.  
1.2.2 Equine gamma herpesviruses (EHV-2 and EHV-5) 
Equine herpesvirus (EHV) type 2 and 5 are gamma herpesviruses that belong 
to the genus Percavirus, with genome sizes of 184 kbp (Telford et al., 1993) 
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and 182 kbp (Wilkie et al., 2015) respectively. EHV-2 and EHV-5 are closely 
related viruses and prior to 1987 EHV-5 was indistinguishable from EHV-2. 
However, studies identifying divergent profiles of restriction fragment length 
polymorphism facilitated differentiation of EHV-5 from EHV-2 (Browning & 
Studdert, 1987). Moreover further sequencing resulted in reclassification of 
EHV-2 and EHV-5 from beta herpesviruses to the family of slower growing 
gamma herpesviruses (Telford et al., 1993). Both EHV-2 and EHV-5 have 
been detected in the Icelandic horse population, where the horses have been 
isolated for more than 1000 years (Torfason et al., 2008), suggesting that the 
equine gamma herpesviruses are not a recently appearing microbial agents in 
horses. The clinical significance of infection with equine gamma herpesviruses 
remains unresolved, mainly because of its worldwide distribution and the high 
prevalence of infection in different horse populations but with only scattered 
reports of possible clinical problems related to these infections.  
     EHV-2 and EHV-5 share many similarities with the human gamma 
herpesvirus Epstein-Barr (EBV) in both their biology and their genetic 
characteristics (Brault et al., 2011; Bell et al., 2006). The average level of 
amino acid sequence similarity between the two viruses and EBV has been 
reported to be 44% (EHV-5) to 46% (EHV-2) (Agius & Studdert, 1994). EBV 
commonly infects humans where >90% of the adult population in the USA are 
persistently infected with EBV whereas the antibody prevalence in children is 
around 50% (Balfour et al., 2013b). EBV is linked to subclinical infection but 
as well associated with mononucleosis (Balfour et al., 2013a), and, like EHV-5 
it has also been associated with pulmonary fibrosis (Vannella & Moore, 2008; 
Mora et al., 2005). Moreover, diseases such as multiple sclerosis (Mechelli et 
al., 2015) and different types of cancers such as Hodgkin´s lymphoma, 
Burkitt´s lymphoma and nasopharyngeal carcinoma (Parkin, 2006) have been 
associated with infection of EBV. Diversity at the whole genome level has 
been identified in EBV, suggesting that genetic variations may be a possible 
explanation for the differences in its pathogenicity (Kwok et al., 2014). 
However, specifically pathogenic strains or genotypes have yet to be identified.  
Gamma herpesviruses infect the horses early in life. By the age of two to 
four months the majority of foals are infected with EHV-2 (Dunowska et al., 
2011; Bell et al., 2006; Murray et al., 1996), whereas infection of EHV-5 
appears to occur some months later in life (Bell et al., 2006; Dunowska et al., 
2002a; Nordengrahn et al., 2002).  
Both EHV-2 and EHV-5 have commonly been observed in clinical healthy 
foals and adult horses (Rushton et al., 2013; Torfason et al., 2008; Bell et al., 
2006; Borchers et al., 2006; Ingram et al., 1978; Kemeny & Pearson, 1970). A 
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higher prevalence of EHV-5 than of EHV-2 has been reported (Hue et al., 
2014; McBrearty et al., 2013; Pusterla et al., 2013; Wang et al., 2007). 
In contrast to earlier reports of non-pathogenicity, EHV-2 has been isolated 
in tracheal aspirates, PBMC or NS from foals with clinical respiratory disease 
more frequently compared to clinical healthy foals (Wang et al., 2007; Murray 
et al., 1996). EHV-2 has also been suggested to have the ability to induce 
pharyngitis (Blakeslee et al., 1975) as well as to predispose foals for 
Rhodococcus equi pneumonia (Nordengrahn et al., 1996).  
In adult horses, EHV-2 has been attributed to clinical respiratory disease 
(Borchers et al., 1997), granulomatous dermatitis (Sledge et al., 2006) and 
keratoconjunctivitis (Rushton et al., 2015; Kershaw et al., 2001) although an 
another study in Austria failed to find any association between detection of 
EHV-2 in conjunctival swabs and ophthalmic findings (Rushton et al., 2013). 
EHV-2 has also been reported to be associated with lower airway inflammation 
and consequently poor athletic performance (Fortier et al., 2013).  
In contrast to previous assumptions of non to low pathogenicity of EHV-5 
(Bell et al., 2006; Dunowska et al., 2002a), selected case reports have recently 
linked EHV-5 with both dermatitis diagnosed with PCR assay performed on 
skin biopsies (Herder et al., 2012) and lymphoma (Vander Werf & Davis, 
2013). Importantly, EHV-5 has also increasingly been associated with the 
severe lung disease equine multinodular pulmonary fibrosis (EMPF) in adult 
horses (Spelta et al., 2013; Poth et al., 2009; Williams et al., 2007). Despite this 
association, the role of EHV-5 in the pathogenesis of EMPF remains to be 
determined, in particular since EHV-5 has been identified in 40-76% of the NS 
obtained from healthy horses (Hue et al., 2014; Marenzoni et al., 2010). It 
remains to be established whether chronic infections of EHV-5 at some stages 
at certain conditions can cause lung fibrosis, or if the disease is rather 
connected to particular point mutations or genotypes. Of note, one horse 
diagnosed with EMPF was identified with a higher load of EHV-5 in the lungs, 
especially within the fibrotic nodules, compared to tissues such as the spleen 
and kidneys (Marenzoni et al., 2011). Those findings have however not been 
verified by comparing the viral load in the lungs and other tissues from healthy 
horses shedding EHV-5. Experimental induction of EMPF has been attempted 
where EHV-5 from two EMPF cases was isolated and thereafter inoculated 
into the lungs of six horses (Williams et al., 2013). While it was difficult to 
detect EHV-5 the inoculated horses, lesions that shared similarities with EMPF 
were subsequently identified in three of the cases at post mortem examination 
performed on 98-108 days after inoculation.  
As both viruses are latent and subject to periodic reactivation, the actual 
site/s of latency in the horse may be of importance in directing appropriate 
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sampling and for understanding possible triggers for recrudescence. It has not 
yet been established where the latency for EHV-5 occur, whereas EHV-2 is 
latent in B-lymphocytes and macrophages (Drummer et al., 1996; Dutta & 
Campbell, 1978), although the Langerhans cells have also been suggested as a 
possible site for latency of EHV-2 (Borchers et al., 2006).  
Due to the frequent detection of equine gamma herpesviruses in what 
appears to be clinically normal animals, the question arises whether actual viral 
load rather than solely presence of the virus may play a role in inducing 
clinical alterations. At least in foals undergoing episodes of respiratory disease, 
no correlation was found with the viral load and the occurrence of respiratory 
disease. (Brault et al., 2011; Bell et al., 2006). Another possible factor related 
to pathogenicity is genetic diversity of viral strains, which has been reported to 
occur in both EHV-2 and EHV-5 (Thorsteinsdottir et al., 2013; Brault et al., 
2011; Sharp et al., 2007; Bell et al., 2006). Those studies where the clinical 
aspects were compared to selected genetic variations of the viruses, were 
unable to identify any association with the genetic diversity. However, those 
studies mainly used older methods for sequencing, which compared to more 
recent next generation sequencing, have limited possibilities to detect new 
strains/genotypes and multiple infections. The large genetic background of 
EHV-2&5 also presents a challenge in detecting possible genotypes that might 
be associated with disease. 
Despite some recent reports questioning the earlier presumed non-
pathogenic nature of the equine gamma herpesviruses (Fortier et al., 2013; 
Williams et al., 2007) the role of these viruses in causing or predisposing to 
clinical abnormalities or to poor athletic performance remains unclear. Hence, 
more detailed knowledge regarding the biology of the viruses and their 
interaction with their host is needed to investigate the role of the equine gamma 
herpesviruses in the healthy well performing horse, as well as in horses with 
clinical disease and/or poor performance 
1.3 Equine rhinitis viruses (ERAV and ERBV) 
Picornaviridae is a large and diversified virus family of small single-stranded 
RNA-viruses with a genome size of about 7.2-8.8 kbp and approximately 30 
nm in diameter. The family includes both human pathogens such as poliovirus, 
hepatitis A virus, rhinovirus and animal pathogens such as foot and mouth 
disease virus and rhinitis viruses. 
The human rhinoviruses are significant respiratory pathogens known to 
cause the common cold and are divided into three strains, which in total 
include more than 150 serotypes (Tapparel et al., 2013). 
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The equine rhinitis viruses were first isolated in Beckenham, England 
(Plummer, 1962) and were previously known as equine rhinoviruses 1-3 within 
the genus Rhinovirus (Steck et al., 1978; Ditchfield & Macpherson, 1965). 
However, genetic studies identified considerable phylogenetic differences 
between the equine rhinoviruses and the other members within the genus of 
Rhinovirus (Li et al., 1996; Wutz et al., 1996). Equine rhinovirus 1 was found 
to be more closely related to foot and mouth disease and therefore renamed to 
equine rhinitis A (ERAV) virus and reclassified to the genus Aphtovirus, 
whereas equine rhinovirus 2 was renamed to equine rhinitis B virus (ERBV) 
and with its three serotypes, reclassified as the so far single member of the 
genus Erbovirus (Black et al., 2005; King et al., 2000). ERAV exists only as 
one serotype and has been reported with a high genetic stability, since it has 
been shown that the genome of the currently circulating ERAV strains are 
highly similar to the original ERAV isolate that was initially described by 
Plummer in 1962 (Diaz-Mendez et al., 2013). 
ERAV can be isolated from the blood several days post infection and from 
the nasopharynx and in faeces for up to a month (Plummer & Kerry, 1962). 
Moreover ERAV has a unique feature among the picornaviruses, since it can 
be shed via urine for a long period of time, up to 147 days in naturally infected 
horses (McCollum & Timoney, 1992) and for at least 37 days in urine from 
experimentally infected horses (Lynch et al., 2013). Studies in the USA, 
Ireland and Australia detected ERAV in post-race urine samples at a frequency 
of 17%, 29% and 23% respectively, suggesting that the persistent presence of 
ERAV in urine may contribute to its maintenance in training yards (TY) 
(Lynch et al., 2013; Quinlivan et al., 2010; McCollum & Timoney, 1992). 
ERAV is spread by direct or indirect contact of secretions from the upper 
respiratory tract or via aerosol inhalation (Burrows, 1970). The shedding via 
urine might also be a possibilities for the virus to spread (McCollum & 
Timoney, 1992). In an early study, horses seronegative to ERAV showed 
clinical signs such as fever and nasal discharge 4-5 days after experimental 
infection, whereas horses identified with antibody titres developed no signs of 
respiratory disease after inoculation (Plummer & Kerry, 1962). However, the 
clinical signs associated with natural infection of ERAV are ranging from mild 
or subclinical appearance (Hofer et al., 1978) to fever, coughing, anorexia and 
nasal discharge (Carman et al., 1997; Studdert & Gleeson, 1978) and were the 
likely cause of at least two Australian outbreaks of respiratory disease (Li et 
al., 1997). 
The clinical manifestation of ERBV is less defined than for ERAV. The 
spread is thought to occur by direct or indirect contact with nasal secretions 
and aerosols (Horsington et al., 2013b). Also for ERBV subclinical infection as 
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well as signs associated with upper respiratory tract disease such as fever, 
cough and nasal discharge has been reported (Diaz-Mendez et al., 2010; 
Carman et al., 1997; Burrows & Goodridge, 1978; Steck et al., 1978). 
Seroconversion of ERAV has been reported to occur among young horses on 
entry to TYs, either without detected clinical signs (Black et al., 2007; Powell 
et al., 1974) or with minor respiratory disease (Klaey et al., 1998). The same 
association has however not been established for ERBV (Black et al., 2007).  
ERAV has been demonstrated as being a zoonotic infection i.e. capable to 
infect humans (Plummer, 1962) and there are also indications that ERBV has 
this capacity. However, despite working in an area with a large majority of the 
horses identified as seropositive to ERAV and/or ERBV (Kriegshauser et al., 
2005), only limited numbers of veterinarians have been identified as 
seropositive to ERAV and/or ERBV. The high seroprevalence of neutralizing 
antibodies to both ERAV (37-90%) and ERBV (71-86%) in horses foremost 
without clinical disease is described worldwide, which indicate that the viruses 
are endemic in horse population (Horsington et al., 2013a; Black et al., 2007; 
Dunowska et al., 2002; Klaey et al., 1998; McCollum & Timoney, 1992; de 
Boer et al., 1979). It also appears that high levels of neutralizing antibodies to 
ERAV can persist in horses for years (Burrows, 1970) which might play a role 
in protecting horses from developing clinical signs at reinfection. These 
observations are supported by a Canadian study where ponies experimentally 
infected with ERAV developed clinical respiratory signs and one year later, 
remained seropositive from the initial infection challenge and failed to develop 
clinical signs with repeated experimental infection (Diaz-Mendez et al., 2014). 
In contrast to the high levels of neutralizing antibodies induced by natural 
infections of equine rhinitis viruses, the antibody levels induced by vaccines 
have been disappointingly low. So far, no commercial vaccines are available 
against the equine rhinitis viruses. Studies have been performed where both 
virion proteins of ERAV (Warner et al., 2001) and plasmid-based DNA 
vaccines (Lynch et al., 2011) have been investigated in order to reach higher 
antibody titres after vaccination. A patent application for an equine rhinitis 
virus vaccine was recently published (Diaz-Mendez et al.), and it may be that a 
vaccine will be available in the foreseeable future. 
Based on these studies it is likely that the majority of infections by ERAV 
and ERBV are mild or subclinical. As a result it has been suspected that the 
equine rhinitis viruses could have an impact on the athletic performance of the 
young horse due to prolonged recovery as well as posing a risk for secondary 
bacterial infection. Despite the controversies regarding the role of subclinical 
rhinitis virus infection in the poor performance syndrome, no reports have 
actually described such infection in association with poor athletic performance.  
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1.4       Poor athletic performance 
When determining the performance of the athletic horse, numerous methods 
have been described, but there is still an ongoing debate upon how to best 
measure or detect poor performance. For example the athletic performance of 
trotters has been evaluated by using an annual index calculated by the French 
national stud, based on the natural logarithm of average earnings per race 
(Leleu et al., 2005). Others have used the opinion of the rider/trainer (Fraipont 
et al., 2011; Widmer et al., 2009) as an indicator for the level of the athletic 
performance whereas field exercise tests (van Erck et al., 2006; Courouce et 
al., 1997) or exercise tests on treadmill (Morris & Seeherman, 1991) have also 
been widely used to further evaluate the performance of athletic horse. The 
treadmill has the advantage to highly standardize the workload and allow 
advanced physiologic monitoring but is not feasible to use for most larger 
studies or in the field at TY, whereas the field exercise test has the benefit of 
being performed at the TY where the horse normally work and is a closer 
reflection of the work undertaken in actual race conditions. 
Clearly, all ways of measuring the athletic performance have their 
advantages and limitations, but since there is no ideal method to truly measure 
the athletic performance of the horse, it remains highly challenging to define 
the presence and degree of poor performance and to determine which specific 
factor or combination of factors impair the performance in a particular 
individual. Poor athletic performance in horses is multifactorial i.e. several 
factors contribute to the risk of developing the condition of disease (Fraipont et 
al., 2011; Martin et al., 2000; Morris & Seeherman, 1991). Certain conditions 
such as lameness and respiratory disease has been reported as the most 
common medical reasons for poor performance and training disruption among 
Thoroughbred racehorses and Standardbred trotters (van Erck et al., 2006; 
Wilsher et al., 2006). Apart from virus infection and viral load, there are 
however other components in individual horses that are even more difficult to 
measure but may affect their full capacity for athletic performance, examples 
are the physical and psychological capacity and genetic makeup.  
 Important factors are for example management factors such as the actual 
physical fitness of the horse, whether the training program is optimized for that 
individual, if the racing schedules is appropriately timed to allow adequate 
recovery periods, and supply of feed suited to meet the needs for elite athletic 
work. The athletic performance can also be influenced on what level of 
competition the horse is participating and thereby earnings per race. In 
addition, it is important to acknowledge that not all horses have the biological 
and mental capacity for top athletic performance, and thus may fail to meet 
owners´ and trainers´ expectations. The important viewpoint is to gain 
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knowledge on relevant factors for performance and health to ensure that the 
talented individuals are not hindered by manageable external factors. 
1.5 Diagnostics of respiratory viruses 
When subclinical viral activity is being considered as a possible cause for poor 
athletic performance in a horse there are a number of diagnostic methods that 
are available. Because the respiratory pathogens are commonly associated with 
highly similar respiratory signs, diagnosis cannot be made on clinical basis and 
reliable laboratory diagnostic tools are necessary to specifically identify them. 
Most of the direct and indirect methods such as PCR assay, virus isolation and 
serology, are highly viral specific. However, to determine the actual effect of a 
virus in a host, i.e. the pathogenicity, the laboratory results are needed to be 
combined with the presented clinical signs. Blood examination identifying and 
quantifying the concentration of inflammatory markers and endoscopic 
visualization of upper respiratory tract can provide some measure of the degree 
of clinical disease in the horse, even if the findings are not specific to viral or 
other infectious agents. Accurate diagnosis of viral infections is important in 
order to allow adequate prognosis and to support the clinical management. To 
appropriate interpret the diagnostic results, it is crucial to be aware of the 
advantages and the disadvantages of the methods currently used in most clinics 
or laboratories. 
1.5.1 Indirect techniques 
Serology  
Serology means testing serum or plasma to identify presence of antibodies or 
antigens which are produced as a response to infection and thus, detection 
precious or ongoing viral infections. A wide range of methods has been 
developed used over the years, for example virus neutralization test (VN), 
complement fixation test (CF) and the enzyme-linked immunosorbent assay 
(ELISA).  
The VN test identifies evidence of infection by detecting mainly IgG 
antibodies. Serial dilutions of sera are tested to determine if sufficient levels of 
antibodies protecting cells from infection with added virus are present (a 
common assay for ERAV or ERBV). This method is highly specific and 
measure the protective effect of the antibodies, but is more expensive and time 
consuming than for example the ELISA and require maintained cell cultures in 
the laboratory.  
In the CF test, serial dilutions of sera are used to identify antibodies, mainly 
IgM, by catching them in a complex together with antigen and complement, 
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thus used to detect presence of antibodies in serum. It is a common diagnostic 
tool for identifying immunological evidence of EHV-1 or EHV-4 infection. 
Since the main target is the IgM antibodies, which decay within 60 days 
(Hartley et al., 2005; Allen et al., 2004), the assay is established to detect more 
recent infections. However, one disadvantage with the CF test is that they are 
often non-specific and therefore the CF test is not able to differentiate for 
example between EHV-1 and EHV-4 since the polyclonal antibodies of EHV-
1/-4 are highly cross-reactive.  
The ELISA method was initially described in 1971 (Engvall & Perlmann, 
1971) and is a highly sensitive method to detect antibodies or antigens. Today 
several variations of ELISA are available to detect either antibodies or antigen 
to a specific pathogen in a sample. This is performed by attach a specific 
antigen to a solid surface (96-well microliter plate), with which antibodies 
from an added sample can form a complex if the sample contains antibodies 
matching the antigen. The complex is detected by an added enzyme that binds 
to the complex. To distinguish IgG antibodies elicited by EHV-1 from those of 
EHV-4 obtained in CF test, a type specific commercially available ELISA has 
been developed (Crabb et al., 1995). However, as single dilutions of sera are 
often used in the ELISA, differences in antibody concentrations between 
samples are not possible to detect. In addition, since the EHV-1/EHV-4 assay 
targets the IgG, caution must be taken regarding time of infection as this 
antibodies can remain at detectable levels long time after initial infection 
(Hartley et al., 2005). 
When using VN and CF tests, the titres can differ between laboratories. 
This can due to the susceptibility of various cell types used in VN assays and 
divergent viral strains utilized in CF and VN tests used in different 
laboratories, which may influence the levels of antibody titres (Hartley et al., 
2005), and therefore cut-off values can vary between laboratories.  
Serological methods have the advantage of being inexpensive and easy to 
perform. However, interpretation of results can be challenging. Knowledge 
about the duration of the production of antibodies as a response to the specific 
virus infection is essential for the interpretation of a positive or negative test 
result. Generally, at least fourfold (two dilutions) or greater increase of 
antibody titres between two sample occasions are required to confirm 
seroconversion or significance with acute infection. Most of the serological 
tests are not enable to distinguish between antibodies relating to vaccination or 
natural infection. 
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1.5.2 Direct techniques 
Virus isolation  
The classical detection assay for viruses which has been used for over 60 years 
(Storch, 2000) is virus isolation in a cell culture or in embryonated eggs, where 
clinical specimens are inoculated into living cells. Different cell culture types 
are required for different viruses, which might be cumbersome for the 
laboratory. The virus is then identified by its cytopathic effect (CPE), a step 
which requires highly experienced laboratory personnel. Isolation of the agent 
in cell culture is the only diagnostic tool that has the advantage of only 
identifying isolates of viable virus, and is best performed on samples from 
acute diseased animals. Virus isolation is a time consuming procedure where 
the required time for detectable CPE varies from 3-6 days for equine alpha 
herpesviruses (Studdert et al., 1970) to >3 weeks for slow growing viruses 
such as the equine gamma herpesviruses (Turner & Studdert, 1970). Another 
disadvantage is that contamination of bacteria or fungus can occur and thereby 
disturb the growth and identification of the virus. 
Polymerase chain reaction (PCR)  
PCR is a technique for detecting presence of specific viral RNA or DNA in a 
sample, providing a reliable and rapid diagnostic tool that is highly specific and 
sensitive. Since its inception in 1985, the advancement of the PCR technique 
has been tremendous and several types of PCR assays are available. The real 
time PCR commonly used currently in laboratory diagnostics has clear 
advantages, foremost its´ high specificity and sensitivity. Moreover, the PCR 
has a larger time frame of detection compared to virus isolation with no need 
of the virus to be alive when it reaches the laboratory. The PCR assay has also 
the benefit of taking less than one day to complete, can allow many samples to 
be analysed simultaneously and that the probes used can increase the 
specificity even further. However, due to its ability to amplify very small 
amounts of nucleic acid, contamination can be a problem (Mifflin, 2007). 
Another concern can be the presence of inhibitors, for example haemoglobin in 
blood samples, that can reduce or even block the amplification of the nucleic 
acid by capturing nucleic acid, inactivate DNA polymerase or disturb the 
composition of ion in the reaction (Radstrom et al., 2004). 
1.5.3 Molecular characterisation 
Sequencing  
The Sanger sequencing, first described in 1977 (Sanger et al., 1977) has been 
the main DNA sequencing method used for the following 30 years. The 
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introduction of next generation sequencing (NGS) has however revolutionized 
the opportunities to study viral diversity and evolution and was selected as the 
method of the year by Nature methods in 2007 (Method of the Year, 2008; 
Schuster, 2008). The several million reads generated in each NGS run gives 
outstanding genetic information of each sequence and provides the possibility 
to detect even rare genetic variants. The development in the field of DNA 
sequencing has been rapid which has led to a reduction in cost per base 
(Pettersson et al., 2009) thus increasing the likelihood of using this technique. 
However, the NGS is still not implemented in routine diagnostic and is mainly 
used for research purposes, to identify and follow strains to e.g. trace disease as 
well as providing possibilities to better understand the pathogenicity of 
microbial agents. 
1.5.4 Inflammatory markers 
The acute phase proteins are synthesized in the liver during different 
inflammatory conditions or infectious diseases (Baumann & Gauldie, 1994). In 
equine medicine concentrations of the proteins fibrinogen and serum amyloid 
A (SAA) in serum are the inflammatory markers commonly used to detect 
nonspecific response to inflammatory or infection. 
Concentrations of SAA (a major acute phase protein) have been shown to 
rapidly increase due to inflammatory stimulus, being elevated in less than 48 
hours in horses infected with EIV (Hulten et al., 1999). Because of its short 
half-life time in serum, reported in laboratory mice to vary between 30 min to 2 
h (KluveBeckerman et al., 1997; Tape & Kisilevsky, 1990; Hoffman & 
Benditt, 1983), the serum concentrations of SAA decrease rapidly after 
resolution of disease and have been suggested to well reflect recovery or the 
response to therapy (Hulten & Demmers, 2002). Moreover, compared to the 
traditional markers (WBC count or plasma fibrinogen) SAA has been found to 
be a more reliable marker in horses to monitor inflammation as well as being a 
prognostic indicator (Belgrave et al., 2013). 
Fibrinogen (a minor acute phase protein) is slower reacting and peaks 
within 1-2 weeks after stimulus and decrease slowly during recovery (Jacobsen 
et al., 2005; Hulten et al., 2002). This makes this biomarker less useful for 
detection and monitoring inflammation than SAA. 
Due to the nonspecific reaction, measurements of acute phase proteins can 
be used as a convenient complimentary tool in the clinical work. However, the 




Endoscopy is a useful tool to visualize the respiratory tract of the horse. It can 
be used to determine the degree of pharyngeal inflammation (Raker & Boles, 
1978), accumulation of mucus in trachea (Gerber et al., 2004), as well as 
grading the degree of pulmonary exercise induced hemorrhage (Hinchcliff et 
al., 2005). Endoscopy is also the gold standard in detection of functional upper 
airway disorders, which can be visualized both at rest or in exercise (McCarrel 
& Woodie, 2015). The bronchoalveolar lavage (BAL) and tracheal wash (TW) 
are sampling methods widely used both in research and in clinical practice, 
which provides samples from the lower respiratory tract that can be used for 
cytology as well as for detection of microbial pathogens. 
Despite the wide range of usefulness for the endoscopy, it cannot be used 
alone to diagnose a specific viral infection. 
1.6 Subclinical viral infections and the equine health/athletic 
performance  
In sport horses, viruses such as EIV, EHV-1&4 are widely known to induce 
clinical signs and that they can affect athletic performance in horses is logical. 
However, if clinical signs are only mild and thereby less clear, attention is also 
directed towards less known respiratory viruses such as gamma herpesviruses 
and rhinitis viruses, which are suggested to have lower pathogenicity, or act 
with mainly subclinical symptoms. Since these viruses have been presumed to 
be low or non-pathogenic, far less research has been performed to clarify their 
biology and interaction with their host. However, whether these viruses truly 
are as innocuous to the horse as previously thought is currently more 
rigorously questioned by the scientific community. Key questions that arise are 
whether these less known viruses are associated with mild clinical disease in 
elite actively racing horses and if they somehow then may impair athletic 





2 Aims of the thesis 
The main aim for this thesis was to investigate the role of subclinical 
respiratory viral infections in actively racing Standardbred trotters. The 
specific objectives were: 
 
 In study I, to describe the first identified case of EMPF associated 
with both EHV-5 and AHV-5 in a Swedish four-year-old horse. 
 In study II, to investigate activity of common respiratory viruses 
over time in a cohort of Standardbred trotters, using available 
diagnostic test including both serology and PCR assays to evaluate 
whether subclinical viral infections were associated with alterations 
in the equine health and/or athletic performance.  
 In study III, to identify the prevalence and the viral load of EHV-2 
and EHV-5 in NS in a cohort of Standardbred trotters and thereby 
evaluate whether infections as well as the obtained viral load, were 
associated with alterations in equine health and/or athletic 
performance.  
 In study IV, to investigate genetic variability in the gB gene of 
EHV-5 in samples from healthy horses over time and also to 
compare genetic results to sequences from samples from a horse 





3 Materials and Methods 
This section provides a brief description of the material and methods used in 
the studies of this thesis work. More detailed information is provided within 
each individual paper. 
3.1 Animals 
The four year-old Standardbred trotter described in study I, was a clinical case 
referred to the Equine Hospital at the Swedish University of Agricultural 
Sciences in Uppsala, with a 10-day history of fever, unwillingness to move, 
tachypnea and mild cough.  
The horses participating in studies II-IV were actively racing 
Standardbred trotters from four different professional training yards (TYs) in 
the area of Mälardalen, Sweden. All horses were training and racing according 
to their regular schedule during the study period and were at the time of 
recruitment healthy and well performing with a mean age of 3 years, (range 2-8 
y, SD 1.33). The horses underwent clinical examination at each sampling 
occasion (performed by a single veterinarian throughout the study), where 
signs of respiratory disease, such as fever (>38.3oC), nasal discharge and cough 
were recorded. The health status was also monitored on a weekly basis 
throughout the study period. 
In study IV, the selected NS were from eight horses with a high viral load 
of EHV-5 identified at two sampling occasions one year apart in study III. 
They were all healthy and well performing at both sampling occasions. In 
addition, the pre-mortem (lung biopsy) and post-mortem samples (lung) from 
the horse with EMPF reported in study I were included. 
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3.2 Study design 
Study I was a case report describing the first Swedish case of EMPF and the 
first case where both EHV-5 and AHV-5 were associated with the disease.  
The study that constitutes the basis for papers II and III was designed as 
a prospective longitudinal study where 66 horses were followed on monthly 
basis from August 2010-August 2011 (13 months).  
In study IV, samples from the horse described in study I and samples 
from eight horses participating in the longitudinal study in paper II and III were 
selected for further genetic analysis of EHV-5.  
3.3 Sampling 
Nasal swabs (NS) and serum samples were obtained from all horses at monthly 
intervals. In the event of clinical respiratory signs or poor performance in the 
interim, additional samples were also collected. The samples were transported 
by car at ambient temperature to the laboratory at the National Veterinary 
Institute (SVA) in Uppsala, where they were stored at 4oC for 1-3 days before 
analysis by multiplex PCR assay on NS and serology on serum samples. The 
NS were then stored at -70oC until the analysis in study III and IV were 
performed. The serum samples were stored at -20oC and the analysis of SAA 
was performed within 1-3 weeks of sampling. 
3.4 Classifications of athletic performance 
The individual athletic performance of the horses was classified using both 
objective and subjective methods, which were registered on monthly basis at 
the same time as the NS and serum samples were taken. 
3.4.1 Objective method 
To objectively classify the performance in each individual horse, they 
performed a standardized field exercise test (SFE) at each sampling occasion. 
The SFE was performed at the TY where the horses ran a predetermined 
distance at a heart rate >210 beats per minute and the running times were then 
compared individually. At each SFE the horses were equipped with a heart rate 
(HR) monitor (Polar Equine CS600X, Polar Electro Sverige AB, Bromma, 
Sweden), to enable the driver to encourage the horse to work at a speed that 
induced a heart rate of 210 beats per minute (bpm). Poor performance was 
based on each individual horse´s running data and was defined as a higher 
running time than the mean of all running times+1 standard deviation (SD) for 
each horse. By using a crossover design (individuals serving as their own 
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control) when objectively measuring the performance, each horse was 
compared to itself which increases the potential to detect true poor 
performance episodes. 
Figure 1. Standardized workload performed by Standardbred trotters in one training yard included 
in study II and III of this thesis. (Photo: Bengt Ekberg). 
3.4.2 Subjective method 
The opinion of the trainer was registered after each SFE or training session 
connected with the sampling occasions. When a trainer deemed that the athletic 
performance in the horse was below what they expected, it was classified as 
poor performance. This method relies on the trainers´ professionalism and 
experience to classify the performance in a qualitative (normal versus poor 
performance) way. 
3.5 Diagnostic methods 
To detect presence and degree of infection of respiratory viruses in the horses, 
several diagnostic methods and tools were used. Different polymerase chain 
reactions (PCR) were performed on NS to identify presence of viral DNA and 
serological methods were used to identify antibodies and to investigate levels 
of a marker of systemic inflammation. Furthermore next generation sequencing 
was utilized to investigate possible genetic variation of the glycoprotein (gB) 
gene of EHV-5. 
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3.5.1 Nested consensus PCR 
The presence of herpesvirus in lung tissue and tracheal wash (TW) from the 
horse with multinodular pulmonary fibrosis in study I, was identified using 
nested consensus PCR assay. This assay was used for detection of a wide range 
of herpesviruses in the sample, since its target region was a segment of the 
DNA polymerase gene that many herpesviruses have in common. This was 
followed by second round amplification and sequencing in order to determine 
which herpesvirus was present in the sample (Ehlers et al., 1999; VanDevanter 
et al., 1996). 
Phylogenetic analysis was performed using the neighbour-joining and the 
Kimura-two-parameter model as implemented in SplitTree4 (Huson & Bryant, 
2006). By that, it was then possible to investigate the relationship between the 
products of EHV-5 and AHV-5 obtained from sequencing and related equine 
herpesviruses. 
3.5.2 Multiplex real-time PCR 
To identify the common respiratory viruses in NS from horses in study II, a 
multiplex real-time PCR assay was used, in which primers targeting the viruses 
EIV, EHV-1, EHV-4, ERBV and EAV were included. Extraction of 
RNA/DNA was performed using a Magnatrix 8000+ robot and the extraction 
kit NorDiag Vet Viral NA (NorDiag AB, Hägersten, Sweden) according to the 
manufacturer´s instructions. Thereafter TaqMan PCR using the primers and 
probes described in study II was performed. Amplicons detected above 
threshold at a quantification cycle (Cq) <40 were considered as positive results. 
3.5.3 Quantitative PCR (qPCR) 
Since no qPCR assay for EHV-2 and EHV-5 were available at the time when 
study III was initiated, we developed and validated two new qPCR assays 
targeting the conserved region of the DNA polymerase gene of each virus. 
Viral DNA was extracted from NS using a Magnatrix 8000+ robot and the 
extraction kit NorDiag Vet Viral NA (NorDiag AB, Hägersten, Sweden) 
according to the manufacturer´s instructions. Applied Biosystems 7500 Fast 
Real-Time PCR System (Life Technologies, Saint-Aubin, France) were used to 
amplify the selected regions of the nucleic acid, using the primers and the 
UPL-probes as are further described in study III. Cq<40 was considered as 
positive. The viral load within each sample, was calculated by linear regression 
using the ten-fold serial dilutions of known concentration of DNA copies from 
the validation of the qPCR assay and the given Cq values. DNA copies 
detected above the threshold at a quantification cycle (Cq) <40 were 
considered as a positive result. 
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The analysis of EHV-2 and EHV-5 were run in two separate assays in order 
to avoid the risk of failure to identify each of them if co-infection occurred. 
Moreover, the conserved DNA polymerase gene was used as the target gene to 
increase the possibility of the assay to detect the virus even if different strains 
were present. 
3.5.4 Next generation sequencing (NGS) 
In study IV a region of the EHV-5 glycoprotein B (gB) in which high 
variability flanked with stable nucleotides could be identified was selected to 
design a new PCR assay, which were followed by NGS. By using this method 
of “deeper” sequencing, genetic variations in that particular segment of EHV-5 
would be detectable and thereby enable unmasking of any multiple infections 
by several strains. The amplicon PCR and library preparation was performed 
according to the Illumina protocol “16S Metagenomic Sequencing Library 
Preparation” with smaller modifications and thereafter sequenced (NGS) using 
MiSeq Reagent Kit v.3 600 cycles on the MiSeq instrument (Illumina) and the 
“Generate FASTQ” workflow. The high quality reads obtained from the NGS 
were trimmed, merged, and phylogenetic analysis were performed in the 
software program Trimmomatic, COPE 1.1.2, MUSCLE and MEGA, 
which are described in more detail in the materials and methods of paper IV. 
The different clinical specimens included in study IV were coded with a 
unique letter for each horse followed by number “1” (first sampling occasion) 
or “2” (second sampling occasion) and the last number (1-3), illustrate the most 
(1) and less (3) common strain within each of the clinical specimens.  
3.5.5 Complement fixation (CF) test 
The CF test was used to investigate presence of mainly IgM antibodies to 
EHV-1 and EHV-4 in serum samples (Kriegshäuser et al., 2005). The CF test 
determines whether there are antibodies in the serum at different dilutions, 
capable of forming an immune complex together with antigen and thus 
becomes fixed by the complement (serum from guinea pig). A fixed immune 
complex is not available to lyse sensitised sheep erythrocytes, resulting in a 
button of erythrocytes in the well. The analysis require two working days. 
3.5.6 Virus neutralization (VN) test 
Antibodies to ERAV and ERBV was demonstrated by VN test (Thomson et 
al., 1976), where serum at different dilutions were incubated with virus (ERAV 
strain 1722/Switzerland and ERBV 5/15/95/Newmarket) on RK-13 cells. After 
three days of incubation at 37±1oC the cytopathogenic effect was determined 
by microscopic examination. 
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3.5.7 Immunoturbidometric assay 
The level of SAA in serum was analysed at the department of clinical 
chemistry at SLU using the immunoturbidometric assay (Hillstrom et al., 
2010), where a level of SAA>20 mg/L was considered positive for systemic 
inflammation (Jacobsen & Andersen, 2007). 
3.5.8 Endoscopy 
In study III 28 horses at the same TY underwent endoscopic examination 
(Endoscope pks 60914, Karl Storz, Tyttlingen, Germany), before and after 
each SFE from April to August 2011 to estimate the visual degree of upper 
respiratory inflammation. The purpose of the examination after SFE was to 
assess the lower airways for presence of fresh blood that could suggest exercise 
induced pulmonary haemorrhage. Images from each examination of the 
pharyngeal region and from the trachea at the level one-meter deep from the 
nostrils were taken and stored electronically for subsequent grading. The 
endoscopic findings were graded at the same occasion by an experienced 
equine clinician blinded to clinical and viral status of the horses. Endoscopic 
scoring of mucus accumulation was performed using the scale of 0-5 as 
previously described (Koblinger et al., 2011; Gerber et al., 2004). 
Accumulation of mucus grade 0 was considered normal whereas all grades >0 
was deemed as excess accumulation of mucus. The score of pharyngeal 
inflammation was marked at a scale of 0-4 (Raker & Boles, 1978), where 
grades 0 and 1 were considered normal.  
 




3.6 Statistical analysis 
The statistical analyses, the graphs and the descriptive statistics were 
performed using the software program STATA, version 11.2 and 13.0 
(StataCorp LP, Texas, USA). P-values <0.05 were considered as statistically 
significant. 
Poor performance was classified in three ways and evaluated separately; 1) 
according to trainer, 2) according to deviation from normal running time or 3) 
either parameter classified as poor performance. 
In study II associations between poor performance and viral respiratory 
infection were investigated by logistic regression analysis including only the 
outcome (assessed in three ways in separate analysis) and the different viral 
activity criteria evaluated in separate logistic models (one per each specific 
combination of exposure and outcome), generating crude odds ratios (ORs). As 
observations were not independent but clustered within horse (up to 13 sample 
occasions per horse) and TY (n=4), the standard errors from the unconditional 
analyses were likely underestimated hence producing overly narrow 
confidence intervals. Therefore, in a second step random effects logistic 
regression models (one per independent variable, i.e. virus infection parameter) 
were performed with random effects for horse and TY and adjusting for age 
and gender.  
Due to the wide range in number of viral copies obtained from the NS of 
individual horses in study III, the viral load was transformed into natural 
logarithms (ln). The chi-squared test was used for comparing the numbers of 
qPCR positive samples per season, age groups and to compare the peak of viral 
load between EHV-2 and EHV-5 within horses. Random effects logistic 
regression models were used to investigate the association between the three 
outcomes poor performance (either subjective or objective method classified 
event as poor performance), clinical respiratory signs or level of SAA against 
the number of virus copies while adjusting for age and gender. Random effects 
for horse and trainer were included in the model to account for the repeated 
measurements within horse and clustering within trainer. Each outcome was 
investigated in a separate model. Random effects logistic regression model was 
also used for investigating associations between presence of either EHV-2 or 
EHV-5 and the upper respiratory inflammation grade, with random effects for 
horse and gender.  
The maximum log likelihood estimation of the random effects logistic 
regression models used in both studies II and III was performed using adaptive 





4 Results and discussion 
In this cohort of 63 elite Standardbred trotters, 96 episodes of poor 
performance were identified over a year, whereas it appeared there was little 
activity of the common respiratory viruses.  
All horses in the study were vaccinated against EIV twice a year, and thus it 
was not surprising that no cases of EIV were detected among them. There was 
minor evidence of seroconversion to EHV-1/-4, but not associated with clinical 
disease and with no connection to episodes of poor performance. 
In contrast, a high seroprevalence of the lesser-known rhinitis viruses 
ERAV and ERBV in our cohort of horses suggested active and wide 
distribution of these viruses. However, based on observations of relatively few 
occasions of seroconversions, as defined by a fourfold rise in antibody titres, 
and limited number of PCR positive samples it was concluded that active 
infection by these viruses was uncommon among seropositive horses. No 
association of activity by either ERAV or ERBV could be associated with 
episodes of poor performance or clinical respiratory disease. Additionally both 
of the equine gamma herpesvirus EHV-2 and EHV-5 were frequently detected 
in most horses throughout the year, although no clinical signs or association 
with events of poor athletic performance were observed. 
Overall, no evidence of an association between presence of low virulent 
viruses and poor performance was found in the studies included in this thesis. 
As that the gamma herpesviruses were so commonly detected in the vast 
majority horses throughout the year, we examined the quantitative changes for 
these viruses in individuals to determine whether actual shed number of viral 
particles changed over time and seasons, and if so whether these changes could 
be related to clinical symptoms and/or impaired athletic performance. While 
there was a clear difference in pattern of shedding between EHV-2 and EHV-5, 
and a seasonal variation of viral load regardless of quantity shed, neither of 
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these viruses was associated with any of the clinical or performance problems 
observed in this group of horses. 
Due to the high prevalence of EHV-5 in healthy horses coupled with its 
association with severe lung disease, genetic variations may explain the 
different clinical outcomes. By using NGS we examined a segment of an 
essential glycoprotein gene of EHV-5 from a subgroup of selected horses. This 
resulted in suggested classification of EHV-5 genotypes not previously 
described. We also showed stability in viral strains over time, however 
dynamics of the strains and genotypes were observed in individual horses over 
time. Since all but one of the horses in the subgroup were fully healthy and 
well performing, and the only horse with severe clinical disease did carry a 
strain of a genotype which was also found in clinically healthy horses, the 
question whether genetic variation have different ability to cause disease, could 
not be answered completely. 
A major strength of these studies is that all horses were monitored with 
regular sampling, health checks and objective exercise testing in a longitudinal 
study over more than a year. On the other hand, one aspect that was a challenge 
in this work, similar to most research that investigates athletic performance in 
the horse, and as will be discussed later, is the lack of precision in measuring 
and quantifying actual episodes of poor athletic performance in individual 
horses.  
4.1 Poor athletic performance 
The classification of athletic performance is mainly described in study II, and 
16% (96 of 584) of the events were associated with poor performance 
(subjective and objective classifications). The trainers classified poor 
performance in 52 of the events and in 45 cases the SFE showed a slower 
running time than normal for that horse which classified it as poor 
performance. The opinion of the trainer and the SFE agreed in only one horse. 
Since the results were obtained from high level TYs run by experienced 
professional trainers, including highly ranked horses based on prize money and 
racing results, larger numbers of poor performance would have been 
surprising. The opinion of the trainer was available at all sampling occasions, 
whereas the SFE was performed in only 327 events, due to external factors 
such as poor race track conditions (high amounts of ice and snow), whether the 
horses were racing the day after or the day before or if they were suffering 
from respiratory disease preventing them from training. 
No association between the events of poor performance and subclinical 
viral activity could be identified, neither in study II nor in study III. However, 
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if the study had been performed in TYs with less successful and less well-
managed horses, it is possible that more events of impaired performance would 
have occurred which in turn could have increased the probability to detect any 
possible associations. Another factor that limited the power of our work was 
the relatively low incidence of infections by EIV and EHV-1&4. To fully 
clarify the possible link, if any, of subclinical viral infections of these common 
viruses to poor performance, examinations of horses during a year that by 
chance had a higher incidence of actual viral infections would be required. 
Unfortunately, longitudinal studies focusing on actively racing horses are 
seldom performed mainly due to the difficulties in assessing these valuable and 
professionally kept animals. Nonetheless these results suggest that subclinical 
infections by well-known respiratory viruses are less common than expected 
and therefore their impact on performance, at least in well-managed horses, 
seems to be low. 
Exercise tests can be performed either at treadmills or in the field (race 
tracks, TYs). One major advantage with treadmills is the possibility to 
accurately standardize the actual work. For example speed and angle of 
inclination can be fixed between tests, and the surface does not change with 
weather conditions. On the other hand the weight bearing effect of the sulky or 
the rider is absent (Gottlieb-Vedi & Lindholm, 1997). Moreover, the treadmill 
has also been suggested to have an impact on the locomotion of some horses 
(Barrey et al., 1993).  The field tests on the other hand have the advantage that 
they to a higher degree reflect the conditions encountered during races. 
However, parameters such as weather conditions and track surface can and will 
vary over a year in particular in countries such as Sweden with very different 
seasons which can prevent comparisons between tests performed over time.  
In the studies included in this theses, it was not practically possible to use 
treadmills to assess the athletic performance. Therefore, we standardized the 
parameters for the SFE as best possible by using a set distance and a set heart 
rate (HR) to ensure blood lactate reached or exceeded the proposed anaerobic 
threshold of ≥4 mmol/l. (Courouce, 1999; Persson et al., 1983). This normally 
correspond to a HR of 200 bpm. Furthermore, the SFE performed used a 
crossover design, so that the same individual was its own matched control at 
different time points (Maclure & Mittleman, 2000). The uncertainty of 
comparison of individual performance between horses can thereby be avoided, 
which is essential when the included horses are at different training stages and 
is an additional advantage with the longitudinal study design.  
Regarding using the opinion of the trainer as a subjective method to classify 
athletic performance, a key disadvantage is that the method is highly 
subjective. On the other hand, horses are generally evaluated for problems of 
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poor performance based on the trainers’ experience and this would support 
including and evaluating this parameter when causes of poor performance in 
race horses is investigated. Moreover, at sampling occasions when the SFE was 
not possible to perform (for example the day after a race), the opinion of the 
trainer could provide information about the performance of the horse. The 
question to the trainers was “did the horse perform as normal/as you expected”, 
to ensure a dichotomous response based on the horse´s actual status, and not 
whether the horse performed as they hoped or wished it to do one day in the 
future.  
Despite careful planning to accurately determine the athletic performance it 
remains a challenge. In study II and III it is possible that impaired performance 
of the horses occurred the week or two before or after the samples were taken 
and thereby was not registered. However, as most horses were examined on 13 
distinct separate occasions over an entire year this work should have captured 
at least a portion of such events in close proximity to each other, and can thus 
not explain the lack of association between poor performance and subclinical 
respiratory viral infection. 
4.2 SAA, a useful tool to detect poor performance and/or 
subclinical viral infection? 
In the longitudinal study described in paper II and III, 10 serum samples were 
identified with elevated levels of SAA. In the 96 events of poor performance 
SAA was above the threshold in six of them. This low prevalence of elevated 
SAA in horses with poor performance reduced the usability of SAA as a 
marker for poor performance. In contrast to an earlier study on endurance 
horses that showed elevations of mean values of SAA in poor and 
intermediately performing trotters (Fraipont et al., 2011), our Standardbred 
trotters did not on most occasions of poor performance present elevated SAA. 
The differences between workload of long distance endurance and the far 
shorter and more intensive work of the trotter race type may have an influence 
on our contrasting findings. However, increased levels of SAA have also been 
identified in endurance horses after successfully have fulfilled races at various 
distances (Cywinska et al., 2012), suggesting a limited diagnostic value of 
SAA also after endurance races. In this study, levels of SAA were not elevated 
in horses without clinical signs shedding EHV-4/ERBV or had high antibody 
titers for ERAV/ERBV. Furthermore, SAA alterations could not be associated 
with either presence or high viral load of EHV-2 and EHV-5 in nasal 
secretions.  
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Since SAA is a non-specific marker of inflammation, elevated levels could 
be due to reasons not associated with infectious diseases. In study II and III, 
high levels of SAA were detected in horses that had wounds, recent castration, 
fever or fractures. This is in line with previous work where elevated levels of 
SAA have been identified at various diseases or conditions, including clinically 
apparent EIV infection (Hulten et al., 1999), tissue damage (Jacobsen et al., 
2005) and post-surgery (Jacobsen et al., 2009; Pollock et al., 2005). 
At the outset of this work we were interested to assess whether SAA could 
be used as a tool for a trainer to reveal subclinical problems of the horse that is 
otherwise clinically normal. However, as a low proportion of the samples in 
total and in horses with poor performance had elevated SAA, makes that the 
acute phase protein appear to not be useful for prediction of such underlying 
subclinical problems that could cause impaired athletic performance. 
4.3 Subclinical infection of common respiratory viruses 
In study II, presence of common respiratory viruses (EIV, EHV-1&4) was 
analyzed using a multiplex PCR assay, which also by design included ERBV 
and equine arteritis virus (EAV). None of the horses were identified with 
nucleic acid from EIV, EHV-1 or EAV in the NS, suggesting that those viruses 
did not commonly occur in our cohort.  
Nucleic acid of ERBV and EHV-4 was identified in five respectively one 
NS, which were obtained from horses with no signs of clinical respiratory 
disease and therefore determined as detection of subclinical infection. 
However, only one of the ERBV positive samples was associated with poor 
athletic performance (according to the SFE) and the horse shedding EHV-4 had 
satisfactory performance based on SFE and the trainer’s opinion. The acute 
phase protein SAA was not elevated in any of the six PCR positive samples, 
and thus of no predictive value in detection of these subclinical viral infections. 
The CF test identified ten paired serum samples in which a fourfold rise in 
antibody titers to EHV-1/EHV-4 could be identified. Since eight of the pairs 
were associated with vaccination against alpha herpesviruses, this suggests that 
there were only two horses that underwent natural infection. Importantly, 
during the periods of seroconversion there were no detectable clinical signs of 
respiratory disease in either horse, which suggests subclinical infection. 
However, subtle and transient clinical signs could have gone undetected by the 
trainers and thereby not been registered since the horses were examined by 
veterinarian on a weekly basis. Nonetheless, there were no events of poor 
performance for these two horses throughout the periods of seroconversion to 
EHV-1/EHV-4.  
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The limited evidence of infection by the common respiratory viruses EIV 
and EHV-1&4 found, suggests a minor role of subclinical infections in our 
cohort of EIV vaccinated actively racing Standardbred trotters. This in turn 
provided an ideal study population to examine other less known viruses such as 
equine rhinitis viruses and equine gamma herpesviruses in relation to their role 
on the health and performance of the actively racing horse. 
4.4 Persistence of neutralizing antibodies of ERAV and ERBV 
over a year  
In the blood samples taken on monthly basis over a year for this cohort (584 
samples) and evaluated for neutralizing antibodies to ERAV and ERBV, only 
2% were completely seronegative to ERAV and only 0.2% were completely 
seronegative to ERBV. These findings are consistent with other studies where 
high seroprevalence of ERAV and ERBV have been reported worldwide and 
suggest the virus to be widespread in horse populations (Horsington et al., 
2013a; Black et al., 2007; Kriegshauser et al., 2005; Klaey et al., 1998; de 
Boer et al., 1979; Holmes et al., 1978). 
     The stability of the levels of ERAV titers indicates that active infection was 
uncommon, and is in accordance with results from an earlier study, where high 
antibody titers to ERAV were maintained for years, (Burrows, 1979), 
suggesting that immunity following infection is long term. 
Only three seroconversions to ERAV were detected during the study period, 
which all occurred at one occasion in one TY without accompanying clinical 
respiratory signs or poor performance from the horses. That these episodes of 
seroconversion to ERAV in the absence of clinical signs occurred in previously 
seropositive horses, supports earlier suggestion that persistent antibodies to 
ERAV are protective against clinical disease during re-infection (Diaz-Mendez 
et al., 2014; Burrows, 1978). Of the eight seroconversions to ERBV (occurred 
in three TY), all animals were clinically healthy, which indicated subclinical 
infection, and were performing satisfactorily. As for ERAV, this also suggests 
that antibodies to ERBV might have a protective effect to prevent clinical 
respiratory disease at re-infection. Clearly, single high titers to ERBV or for 
that matter ERAV, as have been so commonly used in the field in Sweden 
(unpublished data) appear to be of little clinical value to predict recent or 
ongoing infection.    
Figure 3 illustrates the monthly antibody titers to ERBV identified in sera 
from horses in one TY. The cut-off value (1:90, considered as high titer 
according to the SVA laboratory), is marked by a red line. Horse 10 differs 
from the others with its clearly higher antibody titers to ERBV without signs of 
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ongoing infection (fourfold increase in antibody titers or detected in NS with 
qPCR assays), implying that high titers can remain for at least a year without 
being stimulated by new infection. This horse had recently arrived at the stable 
and no information regarding previous respiratory disease or laboratory results 
was available. Since the other horses had consistently antibody titers at lower 
levels to ERBV with no seroconversions, active infection including viral 
shedding was not likely ongoing in Horse 10.  
 
Figure 3. The antibody titres of ERBV during one year, detected in serum obtained from horses in 
one of the training yards described in study II. The red line indicate the threshold of the antibody 
titre 1:90 that is classified as “high level of antibodies” at the laboratory (SVA), where the 
analysis were performed.
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4.5 Prevalence and viral load of EHV-2 and EHV-5 in relation to 
health and athletic performance  
Of the monthly NS´s from the 63 racing Standardbred trotters followed over a 
year 74% (492/663) were positive to EHV-5 and 30% (196/663) were 
identified with EHV-2. Furthermore, as illustrated in table 1 of the samples 
contained both EHV-2 and EHV-5. 
None of the horses were positive at all sampling occasions to EHV-2 
whereas for EHV-5 none were completely negative. This high prevalence of 
both EHV-2 and EHV-5 (table 1), is in agreement with previous studies 
conducted elsewhere (Hue et al., 2014; Wang et al., 2007). Moreover the 
observation that EHV-5 could be detected in 100% of the horses at least once 
during the year illustrates the highly endemic situation of this virus in actively 

















Neg samples  
EHV-2 
238 (68%) 83 (67%) 110 (73%) 36 (90%) 467 (70%) 
Pos samples  
EHV- 2 
110 (32%) 41 (33%) 41 (27%) 4 (10%) 196 (30%) 
Neg samples  
EHV-5  
63 (18%) 49 (40%) 49 (32%) 10 (25%) 171 (26%) 
Pos samples  
EHV-5 
285 (82%) 75 (60%) 102 (68%) 30 (75%) 492 (74%) 
Pos samples  
EHV-2 & 5  
(co-detection) 
100 (28%) 35 (28%) 37 (25%) 4 (10%) 176 (27%) 
Table 1. The numbers and proportions of samples (N) collected on multiple occasions from 63 
high performing trotters in Sweden that tested positive or negative for equine herpesvirus type 2 
(EHV-2) and/or EHV-5 by the qPCR assays. Data were obtained from horses at four different 




The role of EHV-2 and EHV-5 in clinically detectable disease and the 
performance of the athletic horse is debated and information about the pattern 
of viral load regarding gamma herpesviruses in horse population is scanty. In 
this comprehensive work the presence of EHV-2 or EHV-5 could not be 
associated with either clinical respiratory disease or poor performance, which 
suggest that simply shedding of equine gamma herpesviruses has little, if any, 
relationship to impaired performance. Previously, based on detection of EHV-2 
in association with BAL neutrophilia this gamma herpesvirus was suggested as 
a possible factor in poorly performing horses (Fortier et al., 2013). However, 
that study lacked any corroborative information about the athletic performance 
of the horses in the study. The only other report associating EHV-2 with poor 
athletic performance, was a case report that lacked normal controls for 
comparison, describing isolations of EHV-2 from three race horses, presented 
with vague clinical signs and not performing on their normally high level 
(Studdert, 1974). 
Given the above findings, the actual viral load of EHV-2 and EHV-5 in 
nasal secretions was analyzed individually for each sample to map viral load 
instead of simple presence, with the overall goal to assess whether increased 
viral shedding of either, or both, of these gamma herpesviruses could be related 
to alterations in health or performance. A wide range in the number of copies 
identified was observed, where between 0-54652 (mean 1528, standard 
deviation 19979) copies/µL in nasal filtrate were obtained for EHV-2 and for 
EHV-5 a range of 0-909293 (mean 14813, standard deviation 100431) 
copies/µL. As shown in figure 4a and b, considerable variation regarding the 
viral load of EHV-2 and EHV-5 was found both within and between individual 
horses, whereas no temporal association between peaks of viral load for EHV-
2 and EHV-5 was observed. While some of the variation may have been 
related to the challenge to obtain representative numbers of viruses within each 
NS, the wide fluctuations are striking and individual immune response or 
stimulating factors controlling the re-excretion might be explanatory factors. 
Others have suggested the genetic make-up of individuals, especially the 
heterogeneity of the major histocompatibility complex loci, as an important 
factor for susceptibility to infectious diseases (Hedrick, 2002). This may be one 
key explanation for the high variation of viral load in horses closely housed at 
one TY, which were the same age and bred at the same stud farm (i.e. horses 
33-38 of figure 4a and b).  
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Figure 4. The viral load of EHV-2 (a) and EHV-5 (b) over time in nasal secretions from 54 of    
the Standardbred trotters included in study III. For descriptive purposes the copy numbers were 
transformed into natural logarithms to show viral load shed in nasal secretions by each        




Despite our finding of periods of very high and low viral shedding of EHV-
2 and EHV-5 within individuals over time, there appeared to be no association 
of viral load of either virus alone or together, with clinical respiratory disease 
or episodes of poor athletic performance.  
A seasonal variation in detection of the two viruses was observed. EHV-2 
was most commonly identified during the winter where 44% of the samples 
were positive compared to only 17% of the collected samples during summer. 
EHV-5 on the other hand had the highest proportion of positive samples during 
spring (80%) and the lowest number of EHV-5 positive samples was also 
identified in the summer (67%).  
Seasonal variation was also found quantitatively, where the mean of the 
shed numbers of copies were highest in spring for EHV-2 (mean 4385 
copies/µL) whereas EHV-5 had its highest (24396 copies/µL) average 
shedding during summer. The lowest mean numbers of copies of EHV-2 was 
shed in summer (122 copies/µL) and in the autumn for EHV-5 (10230 
copies/µL). The observed seasonal variation in viral load between EHV-2 and 
EHV-5 suggests that these two closely related viruses have different infection 
patterns, but this appeared to have no relationship to occurrence of clinical 
abnormalities. Previously, EHV-2 and EHV-5 have been identified at different 
periods of time in foals, suggesting epidemiological differences (Bell et al., 
2006), which is in line with our study indicating that EHV-2 and EHV-5 have 
different patterns of infection. These differences suggest that the two viruses 
interact with their host in separate ways and separate latency sites might occur. 
A subgroup of the horses underwent endoscopic examination, by which a 
high percentage were classified with pharyngeal inflammation scores of ≥2 
(64%). This amount of visible pharyngeal inflammation was not surprising, 
since 22 of the 28 horses were four years or younger. However, presence or 
viral load of EHV-2 or EHV-5 had no correlation to pharyngeal inflammation 
score or mucus accumulation. The grade of pharyngeal inflammation was 
actually significantly lower in horses with qPCR positive result of EHV-2 
(P=0.03) compared to the horses that tested negative for EHV-2. Despite 
earlier reports that found EHV-2 to be the most prevalent herpesvirus in 
tracheal wash from horses with clinical respiratory disease (Fortier et al., 
2009), we found no association between EHV-2/-5 in nasal secretion and 
pharyngitis or presence of mucus, which suggests that subclinical infection of 
equine gamma herpesviruses is a minor risk factor for clinically unnoted 
pharyngitis diagnosed by endoscopy.  
Due to their ubiquity in horses, presence of equine gamma herpesviruses is 
not sufficient to cause disease or affect performance. No evidence of 
association could be found between the viral load of EHV-2 and/or EHV-5 in 
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663 samples, and clinical disease or poor athletic performance. Therefore, 
additional focus on possible strain variations and genotypes of equine gamma 
herpesviruses is needed to further understand the pathogenicity and to possibly 
explain the conflicting observations of the viruses and their impact on equine 
health. 
4.6 Genetic variation of EHV-5  
Recent case reports have suggested an association between EHV-5 and EMPF. 
The pathogenesis of EMPF is however not fully understand and since a high 
prevalence of EHV-5 also has been described in healthy horses, genetic 
analysis could provide further understanding of the virus and its interaction 
with the host. EHV-5 has a large genome which over the years has been little 
investigated and it was only recently that the whole genome has been 
sequenced (Wilkie et al., 2015). Against this background, NGS was used in our 
work to further analyse a segment of the EHV-5 gB gene over time in nine 
individual horses (eight healthy, one with EMPF) to explore any genetic 
differences in the EHV-5 detected in horses included in our studies. 
In this work, 27 different nucleotide sequences (i.e. strains), representing 11 
unique sequence types of the partial gB gene of EHV-5 were identified. Some 
individual horses were infected by up to three different strains at the same 
time. Phylogenetic analysis of the strains resulted in detection of four separate 
clusters which are here suggested as genotypes (I-IV) of the EHV-5 gB gene 
(figure 5). Two of the identified genotypes (I and II) did not match with any 
previously described strains. The diversity between strains in the phylogenetic 
tree within the four divergent genotypes was less than 2% (0 nucleotides (I), 2 
nucleotides (II), 0-3 nucleotides (III), 0-8 nucleotides (IV)). Between the 
genotypes, apart from genotype I and II that diverged by only 9 nucleotides, 
the divergence ranged from 19-81 nucleotides, where genotype IV diverged 
most (by 81 nucleotides between genotype III and IV). This results revealed a 
homology of 83.8-95.6% between genotypes of the EHV-5 gB gene, which is 
highly similar to what have been described both within and between the four 
detected genotypes (based on the gB gene) of the beta herpesvirus, human 
cytomegalovirus (CMV) (Chantaraarphonkun & Bhattarakosol, 2007; Chou & 

















































































































































































































































































































































































































































































































































































A conserved cleavage site for all strains at aa position 111-114 in our gB 
segment of EHV-5 was detected, which is in agreement with another study 
where the cleavage site of gB gene was shown to be essential in EBV for the 
cell-cell fusion of the virus (Sorem & Longnecker, 2009). Moreover, we 
observed a higher nucleotide variability closer to the cleavage site, which is 
supported by a study of the gB gene of EHV-5 and seven other herpesviruses 
(among them EHV-2), where the same cleavage site was identified and 
insertions and deletions mainly occurred close to the cleavage site (Holloway 
et al., 1999). 
The four genotypes were distinctly separated on nucleotide level, as well as 
on amino acid (aa) level (figure 5). In total five different aa sequences were 
identified, where genotype I-III resulted in three different aa sequences for 
each genotype, and the strains from genotype IV resulted in two unique aa 
sequences. The results shows that aa sequences within each genotype seem 
to be strongly conserved, but between genotypes they differ considerably. This 
might affect the structural or conformational constraints on this gB segment, 
possibly causing genotypes to interact differently with the host. Strains of gB 
genotypes (I and II) has not been described before and might be specifically 
circulating in Sweden, since differences in the geographical distribution of 
different genotypes has been described for EBV (Abdelhamid et al., 1992). It 
might however also reflect the limited genetic information of EHV-5. The 
selected reference nucleotide sequences of the gB gene (figure 5) were strains 
originating from three different continents (North America, Australia and 
Europe). The two European isolates (genotype III and IV) originate from the 
horse population in Iceland, which has been isolated from direct contact with 
other horse populations for more than 1000 years (Torfason et al., 2008). 
Icelandic horses are however frequently exported from Iceland to the 
Scandinavian countries, but are rarely in direct contact with professionally 
trained Standardbreds.  
Dynamic of EHV-5 gB gene over time 
Three different patterns of EHV-5 infection (based on the partial gB gene) over 
time were detected in this study. The strains referred to in this section are 
illustrated in figure 5. Infection of a single identical strain (genotype I) on both 
sampling occasions occurred in four horses (R, V, W and Z), which illustrates 
a high stability of the viral strains over time. Similar findings has also been 
described for the human herpesvirus type 6 (HHV-6, a beta herpesvirus), where 
the identical strain from one genotype (based on the gB gene) was detected in 
the same patient at two different time points (Achour et al., 2008).  
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The second pattern was infection of two strains from different genotypes 
with varying proportions, which was illustrated in two horses (A and U). Horse 
U shed two strains, one from genotype I and the other from genotype III at 
both sampling occasions, but the proportions shifted over time. In horse A, also 
the proportions of the strains (genotype II and III) varied over time as 
illustrated in table 2, but not as striking as for horse U. This highlights the 
influence of the host-virus-environment interaction and may also be explained 
by the viability of different strains.    
In the third pattern appearance and loss of different strains over time was 
observed in two of the horses (X and Y). Horse X was first identified with 
strains of genotype I and III, one year later an identical sequence from 
genotype I was detected together with a new strain classified as genotype IV, 
and the strain of genotype III was absent. Horse Y first harbored three strains, 
which were classified in three different genotypes (I, III and IV). One year later 
genotype IV could be detected. This third pattern feature that the number of 
strains and genotypes that infect adult animals can be variable, but also the 
high stability of strains over time. Moreover, the described changes in horse X 
suggests that infection with a new strain of EHV-5 occurs. Further studies are 
needed to investigate whether this stability is mainly related to host, virus 
and/or environmental factors. 
The observations in our work shows a range of interactions between EHV-5 
and the host over time, where the viruses persist in some horses and others 
have a more dynamic infection pattern including strains from different 
genotypes. The eight healthy horses were at the same TY and presumably 
under the very similar environmental infection pressure. Therefore, the 
different patterns of viral interaction with the host suggests that individual 
characteristics such as strain and the genetic background or the immune 
responses to EHV-5 in the host, may play important roles in the viral dynamic 
over time. 
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4.7 EMPF, associated with gamma herpesviruses?  
The uncommon but severe chronic lung disease equine multinodular 
pulmonary fibrosis (EMPF) was described for the first time to be associated 
with EHV-5 in 2007 (Williams et al., 2007). In study I in this thesis, the two 
gamma herpesviruses EHV-5 and AHV-5 were detected in lung biopsy, TW 
samples and in the lung lobes obtained from necropsy, from a horse where both 
the clinical signs and the histological changes within the lung corresponded to 
EMPF. At necropsy multifocal, firm and well-demarcated nodules were found 
to affect all lung lobes (figure 6).  
  
 
 This horse had no history of contact with donkeys. The knowledge of AHV-5 
in horses is scanty, even if the virus has been identified in healthy horses 
(Rushton et al., 2014). The co-detection of EHV-5 and AHV-5 in an EMPF 
case suggests that AHV-5 may play a role as a co-pathogen, and that it 
deserves further attention in the attempt to understand the etiology of EMPF. 
On the other hand, genetic diversity of EHV-5 must also be included as a factor 
to consider regarding why only some horses infected with EHV-5 and/or AHV-
5 develop EMPF. 
As illustrated in figure 5 the sample from the EMPF horse was classified as 
genotype III, and that it was highly similar (one nucleotide divergence) to the 
nucleotide sequence (KC715730) obtained from another EMPF case diagnosed 
in USA (Williams et al., 2013). However, other healthy horses in our study IV 
were also infected with strains of the same genotype. Furthermore, the EMPF 
case was infected with only one strain of genotype III, whereas healthy horses 
in which genotype III was detected were co-infected with multiple strains 
simultaneously, and it cannot, be excluded that genotypes or combinations of 
strains might be of clinical importance. In comparison, human infection by 
multiple strains of CMV has been suggested to cause more severe clinical 
manifestations in immunocompromised individuals, than infections with a 
Figure 6. A section of the lung 
from the horse diagnosed with 
EMPF. The multifocal fibrotic 
nodules are large and distinct and 
only limited areas of normal 
parenchyma is detectable. (Photo: 
Rodrigo Grandón). 
53 
single variant (Coaquette et al., 2004). Even though EBV has been associated 
with idiopathic pulmonary fibrosis (IPF) (Tang et al., 2003) and with several 
types of cancer (Parkin, 2006), the pathogenesis is still unknown. To date 
genomic diversity of EBV has been identified, but if the pathogenicity is 
related to strain variability remains to be clarified (Palser et al., 2015; Kwok et 
al., 2014). 
4.8  The choice of study design and its impact on the results  
The study design has an impact on how reliable and robust the results are, and 
also influence what conclusions that can be made. Common epidemiological 
studies used in veterinary medicine are: Descriptive studies (case-reports and 
case series), experimental studies and observational studies (longitudinal, case-
control and cross-sectional). 
Case-report (study I) is a suitable study design to describe a clinical 
observation in particular if it is a new disease or a new manifestation of a 
previously described disease. It does not tell anything about the prevalence and 
does not involve any comparisons with other healthy or diseased animals. The 
detection of both EHV-5 and AHV-5 in a horse with EMPF, was not 
previously described and therefore of interest to report. However, the evidence 
of findings in case reports is rather low but may be case-unique. 
  Study II and III were based on a longitudinal study, which was 
characterized by a cohort (a selected number of animals) that was followed 
over time with health status registered during the study period. The cohort 
study design has the highest ability to identify an association between exposure 
and outcome given that the individuals are healthy at the start and that the 
exposure can be adequately estimated. However, if the number of cases in a 
certain time frame is low this study design is less useful. Instead, it is more 
feasible to use the case-control design where the exposure level can be 
compared among cases and controls to evaluate whether the exposure is related 
to the outcome. Another commonly used observational study is the cross-
sectional study design that is characterized by a selected group of animals, 
where the healthy and diseased animals are studied at one single time point. In 
the hierarchy of cause-effect relationship the longitudinal study is known to be 
the most informative among the observational study types (Pfeiffer, 2010). By 
using the longitudinal study design instead of a cross-sectional study in paper 
II and III it was possible to observe how the antibody titres of ERAV and 
ERBV remained stable at high levels over a year. It was also possible to 
demonstrate that individual horses can shed EHV-2 and EHV-5 for several 
months, and to follow fluctuations of viral load of EHV-2 and EHV-5 over 
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time. It can be hypothesized that association of poor performance or clinical 
disease with presence of any the viruses, could have been found if a case-report 
or cross-sectional study design would have been used. A case report could for 
example have suggested association with poor performance and a high titre of 
ERAV/ERBV. In that case, we would not know that the titres can remain on 
high levels for months, and it would therefore have been easy to draw the 
conclusion about a strong association that does not exist. The same could 
happen in a cross-sectional study even if more samples are obtained. Therefore, 
longitudinal studies are important to verify causality between disease and a 
possible causative agent, given that the disease is not too rare in the population.  
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5 Conclusions 
To investigate the role and the prevalence of subclinical viral infections and 
their possible association with poor athletic performance, 63 elite Standardbred 
trotters were followed by monthly sampling in a prospective longitudinal study 
over a year.  
 
 SAA detected in serum could not be used to detect subclinical viral 
infection as elevated levels were very rarely found in these samples.  
 
 The incidence of subclinical infection of common equine respiratory 
viruses (EIV, EHV-1 and EHV-4) in this cohort of horses was low. 
 
 Antibody titres to ERAV and ERBV can remain on high levels in 
serum for at least a year without being associated with disease, poor 
performance or viral activity. 
 
 A high prevalence of EHV-2 (30%) and EHV-5 (74%) was identified 
in nasal secretions from the horses during the study period. 
 
 Neither the presence of EHV-2 and/or EHV-5 nor their viral load 
could be associated with clinical respiratory disease or poor athletic 
performance. 
 
 The viral load of EHV-2 and EHV-5 were identified with divergent 
patterns of infection, which suggest different biological activity. 
 
 Genetic analysis of the EHV-5 gB gene allowed classification into 
four genotypes (I-IV).  
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 Individual horses were co-infected with up to three divergent strains of 
different genotypes of EHV-5 gB gene, and different patterns of 
infection were identified. The strains showed high genetic stability 
over time, and some of the horses were infected with identical strains 
one year apart. In other horses the strains were genetically stable but 
the proportion or each strain shifted. Changes in strains and genotypes 
were also shown to occur over time.  
 
 In a case report of a four-year-old horse EMPF was suggested to be 
associated with infection of both AHV-5 and EHV-5.  
 
 The EMPF case was infected with only one strain of genotype III of 
EHV-5. Clinical healthy horses were also found to be infected with 
this strain although they were carrying other strains simultaneously.  
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6 Future perspectives 
The field of poor performance is a large and complex topic, mainly since 
multiple causes are often involved and “gold standard” is lacking in determine 
the athletic performance. The work in this thesis have added information about 
low virulent infections of both well-known and less investigated equine 
respiratory viruses and identified them to affect the athletic performance little 
as long as no clinical signs occurred. However, further work in standardize the 
determination of athletic performance would highly benefit future research in 
the field of elite horses and their performance. For example standardized 
protocols including HR, speed and distance for each discipline, could facilitate 
comparison between studies. 
 
Since horses seropositive to equine rhinitis viruses in study II developed no 
signs of respiratory disease when viral activity occurred, the antibodies induced 
by natural infection seem to be protective against clinical respiratory signs. The 
majority of the horses included in this work had seroconverted before the age 
of 2 years old. The need of a vaccine against ERAV can therefore be argued, 
since problems associated with both rhinitis viruses were limited in this cohort 
of seropositive racing Standardbred trotters. The horse population that might 
benefit from a vaccine is young horses seronegative to ERAV, which thereby 
could be protected from possible clinical disease, caused by infection of ERAV 
in association with entering TY.  
 
To further understand the role of EHV-5 in the equine population, the 
described amplicon PCR followed by NGS (study IV), could be performed in a 
larger number of horses from different geographical areas. That would provide 
information of the geographical distribution of different EHV-5 gB genotypes 
and their possible clinical importance. Further genetic work is needed to clarify 
the interaction between EHV-5 strains in individual horses, and thereby 
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understand the clinical consequences of multiple or single infection. Of interest 
would also be to focus on the interaction between strains over time, if new 
infection occurs frequently and if selective latency or clearance appear as a 
common state for the gamma herpesviruses.  
 
A dynamic of EHV-5 gB genotypes was in this thesis work identified in 
individual horses over time. To further study this dynamic, the analysis used in 
study IV would be of interest to perform on samples obtained from horses both 
more frequently (e.g. monthly samples over a year), and over a longer study 
period (at least two years). That kind of studies could provide further 
information of the interaction between the virus and its host and how the 
pattern of the EHV-5 strains varies over time.  
 
The genetic analysis performed in study IV, identified only one EHV-5 gB 
strain classified as genotype III in the EMPF case from study I. Although 
conclusions based on a single case must be drawn with great caution, it would 
however be of interest to analyse samples from several horses diagnosed with 
EMPF (together with healthy control animals), by using the sequencing method 
described in study IV. That might reveal if single infection by strain of EHV-5 
gB genotype III is associated with the severe lung disease. Moreover, the 
nucleotide and aa sequences of different EMPF cases could be compared and 
maybe similarities or characteristics could be found. That information could be 
one step closer to a clarification to the role of EHV-5 in the pathogenesis of 
EMPF. 
 
The role of EHV-2 and ocular disease is another interesting question of the 
gamma herpesviruses, that is not fully understood and where genetic analysis 
might clarify the role of this complex virus. Eye swabs identified with EHV-2 
from horses with ocular disease (and healthy controls), could be compared by 
using amplicon PCR assay designed for a suitable gene segment of EHV-2 
followed by NGS as described for EHV-5 in study IV. This might give 
valuable information about possible genotypes and strains, which could be one 
way to support or reject causality of ocular disease and EHV-2. 
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7 Populärvetenskaplig sammanfattning 
7.1 Bakgrund 
Luftvägsvirus är allmänt kända för att orsaka kliniska symptom såsom feber, 
hosta, nedsatt allmäntillstånd och näsflöde hos hästar över hela världen. 
Luftvägsproblem anses dessutom tillsammans med hälta vara de främsta 
medicinska orsakerna till att tävlingshästar underpresterar, missar 
träningsdagar eller inte kommer till start. När ett virus orsakar tydliga 
sjukdomssymptom hindrar de en häst från att träna eller starta på tävling, men 
man vet också att virus kan infektera en häst utan att ge tydliga symptom (s.k. 
subklinisk infektion). Det är oklart huruvida sådana subkliniska 
virusinfektioner påverkar hästarnas prestation och hälsa.  
Det virus som över hela världen orsakar flest utbrott med luftvägssymtom 
är hästinfluensa (EIV), som spelar stor roll dels för hästarnas hälsa och dels är 
av ekonomisk betydelse för hela hästnäringen eftersom tävlingsbanor kan 
tvingas stänga och många träningsdagar kan gå förlorade. Andra vanliga 
luftvägsvirus är herpesvirus (EHV) typ 1 och typ 4 som är kopplade till både 
tydliga sjukdomssymptom med också till subklinisk infektion. Det är oklart hur 
vanligt förekommande subklinisk infektion av dessa virus är hos tävlingshästar 
och om de i sådant fall har samband med nedsatt prestation. Subklinisk 
infektion av rhinitvirus typ A och B (ERAV och ERBV) har i Sverige däremot 
ofta misstänkts orsaka nedsatt prestation hos framförallt travhästar, men 
påståendet saknar vetenskapligt stöd. 
Herpesvirus är kända för att efter infektion stanna kvar på olika platser i 
kroppen hos sin värd och vara vilande (s.k. latent infektion), för att sedan 
aktiveras vid olika typer av yttre stimuli som stress eller annan sjukdom. EHV 
typ 2 och 5 är två herpesvirus som har hittats hos friska individer men också 
sjuka hästar, t.ex. har EHV-5 associerats med fall av den allvarliga och 
kroniska lungsjukdomen equine multinodular pulmonary fibrosis (EMPF). Det 
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saknas studier om dessa herpesvirus kan försämra prestationen vid subklinisk 
infektion och få diagnostiska metoder finns tillgängliga för att påvisa dem.  
Det övergripande syftet i den här doktorsavhandlingen var att med hjälp av 
olika diagnostiska metoder undersöka förekomst av dessa virus hos 
högpresterande travhästar på elitnivå, för att se om de har ett samband med 
nedsatt prestation eller ej. Vidare ville vi undersöka om den utsöndrade 
virusmängden av EHV-2 och EHV-5 kan relateras till sjukdom och om olika 
genetiska varianter av EHV-5 förekommer. 
7.2 Sammanfattning av studier och resultat 
Under ett års tid följde vi 63 travhästar hos fyra olika svenska proffstränare. 
Hästarna provtogs varje månad med både blodprov och nässvabb, samtidigt 
som deras prestation utvärderades med hjälp av arbetsprov och tränarnas 
bedömning. Hästarnas hälsostatus övervakades kontinuerligt under studietiden 
av veterinär. Totalt togs 663 prover under studietiden. 
Majoriteten av hästarna hade förhållandevis höga antikroppsnivåer mot 
ERAV och ERBV i sina blodprov och många hästar hade stabilt höga nivåer 
under hela studien. Endast i fåtalet fall kunde en fyrfaldig stegring (tecken på 
akut infektion) av nivåerna ses. Detta tyder på att både ERAV och ERBV är 
vanligt förekommande hos tävlande travhästar och att endast ett blodprov med 
en hög antikroppsnivå inte betyder att hästen nyligen varit infekterad av 
viruset. Vidare stödjer våra resultat andra studier där hästar med höga 
antikroppsnivåer mot ERAV och ERBV sällan verkar uppvisa kliniska 
symptom. I den här studien kunde heller inget samband ses mellan subklinisk 
infektion av ERAV eller ERBV och nedsatt prestation hos travhästarna. 
Inga fall av subklinisk infektion av EIV och EHV-1 kunde konstateras. 
Vidare kunde de få detekterade fallen av subklinisk infektion med EHV-4 inte 
korreleras till nedsatt prestation. 
För att undersöka förekomsten av EHV-2 och EHV-5 hos hästarna togs en 
PCR analys fram som detekterar nukleinsyra för de båda virusen i 
nässvabbprov. Närmare tre fjärdedelar och omkring en tredjedel av alla proven 
visade sig innehålla EHV-5 respektive EHV-2. Mängden virus som 
utsöndrades vid de olika provtagningstillfällena varierade kraftigt, men varken 
mängden eller påvisande av de två virusen kunde relateras till nedsatt 
prestation eller kliniska sjukdomssymptom hos någon av hästarna. 
Avhandlingen innefattar också en fallrapport från en travhäst (ej relaterad 
till någon av proffstränarna), som drabbats av lungsjukdomen EMPF. Hos den 
hästen kunde både EHV-5 och åsneherpesvirus typ 5 (AHV-5) påvisas i 
lungsköljprov, lungbiopsi och i lungvävnad vid obduktion. 
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I den fjärde studien inkluderades prover (nässvabb) tagna med ett års 
mellanrum från åtta travhästar hos en av proffstränarna samt lungprov från 
hästen diagnosticerad med EMP. En del av genen som kodar för ytproteinet 
glykoprotein B (gB) hos EHV-5 undersöktes med hjälp av nyutvecklade 
sekvenseringsmetoder. Den undersökta gB genen kodar för ett protein som är 
essentiellt för att viruset ska kunna ta sig in värddjurets cell. Fylogenetiska 
analyser visade att hästarna vid samma tillfälle kunde vara infekterade med upp 
till tre olika stammar. Vidare kunde de olika stammarna delas in i fyra tydligt 
separerade genotyper (I-IV), varav två innehöll gensekvenser som inte 
beskrivits tidigare. De olika stammarna visade sig vara mycket stabila över tid 
med få mutationer. Några av hästarna hade identiska infektioner av EHV-5 
över tid medan det hos andra skedde förändringar över året där både ny 
infektion och reduktion av stammar och genotyper kunde ses. 
7.3 Slutsatser 
Endast ett blodprov där en hög antikroppsnivå mot ERAV eller ERBV har 
påvisats betyder inte att hästen nyligen har infekterats med viruset eller att de 
orsakat något problem hos hästen. Parprov med två till tre veckors mellanrum 
med minst en fyrfaldig stegring av antikroppstiter krävs för att konstatera 
aktiv/nyligen genomgången infektion av ERAV/ERBV. 
Både EHV-2 och EHV-5 är vanligt förekommande hos svenska travhästar, 
men enbart detektion från nässvabb eller hög utsöndring av dessa virus kan 
dock inte kopplas till sjukdomstillstånd eller nedsatt prestation. 
Både EHV-5 och AHV-5 kunde påvisas i lungan hos en häst som 
diagnosticerats med EMPF. Genetiska analyser kunde klassificera EHV-5 från 
den drabbade hästen till genotyp III. Även några av de friska hästarna bar 
också stammar av EHV-5 från samma genotyp 
De genetiska analyserna för delar av gB genen hos EHV-5 gav nya 
kunskaper i hur viruset agerar med sitt värddjur. Våra studier tyder på att det 
finns minst fyra olika genotyper av EHV-5 som alla kodar för olika aminosyra 
sekvenser. Detta gör att de har förutsättningar för att interagera på olika sätt 
med sitt värddjur. Ytterligare studier krävs för att förstå hur förekomst och 
spridning av de olika genotyperna kan förklara olika sjukdomstillstånd som 
setts i samband med dessa infektioner. Vidare är den beskrivna metoden för 
sekvensering av delar av gB genen hos EHV-5 användbar vid uppföljande 
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